AEON Biopharma, Inc. (AEON) Stock

AEON Biopharma, Inc. (AEON) is a Healthcare stock trading at $0.19 (as of 2026-08-21), with a market capitalization of $5.12M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

AEON Biopharma, Inc. is a biopharmaceutical company developing botulinum toxin products for medical conditions. Its pipeline includes a 900 kD botulinum toxin complex (ABP-450) aimed at migraine, cervical dystonia, and gastroparesis.

Understand AEON Biopharma, Inc.: how it makes money

AEON Biopharma develops botulinum-toxin based biopharmaceutical candidates, including ABP-450 (900 kD botulinum toxin complex) for conditions such as migraine, cervical dystonia, and gastroparesis, and advances them through clinical development as a way to ultimately become therapies.

AEON Biopharma’s profit model depends on whether its botulinum-toxin programs generate clinically meaningful results in trials (like ABP-450 in chronic migraine), since the company is focused on developing treatments rather than selling an established, recurring product.

Business quality (Mixed): Clear clinical focus (ABP-450 in migraine), but the provided chronic migraine efficacy comparison includes high p-values versus placebo, which makes statistical differentiation less compelling based on these specific trial metrics.

Bull case

  • Responder rate is higher at the 150 Unit Dose versus placebo: In the chronic migraine study, the Migraine Responder Rate (At Least 75% Reduction) at 150 Unit Dose is 34%, compared with 23% on placebo.
  • Patient global impression shows stronger improvement at higher dose versus placebo: Patient Global Impression of Severity Improvement (Weeks 21 to 24) is 1.0 at 195 Unit Dose versus 0.6 on placebo.

Bear case

  • Provided p-values versus placebo are not low: The P-Value for Statistical Significance of 150 Unit Dose vs Placebo is 0.91, and the P-Value for Statistical Significance of 195 Unit Dose vs Placebo is 0.36.
  • Placebo change is similar to the active-dose mean reduction: Mean Reduction in Monthly Migraine Days on Placebo (Weeks 21 to 24) is 8.4, while the mean reduction is 8.5 at the 150 Unit Dose and 7.7 at the 195 Unit Dose.
Valuation — source: SEC EDGAR (first-party)
Price$0.19
Market Cap$5.12M
FCF Yield-91.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$3.71M
Net Margin172.0%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderDauntless Investment Group, LLC ($2.49M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORobert Bancroft
Employees5
CountryUS
IPO Date2023-07-24

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • CNS Pharmaceuticals, Inc. (CNSP)
  • Xenetic Biosciences, Inc. (XBIO)
  • Exicure, Inc. (XCUR)
  • Apimeds Pharmaceuticals US, Inc (APUS)
  • Enveric Biosciences, Inc. (ENVB)
  • Processa Pharmaceuticals, Inc. (PCSA)
  • Cadrenal Therapeutics, Inc. Common Stock (CVKD)
  • PMGC Holdings Inc. (ELAB)
AEON earnings history · AEON institutional & insider holders · AEON KPIs & operating metrics · AEON financials · AEON investor presentations & press releases · AEON SEC filings · AEON peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.